目的评价祛邪胶囊对晚期结直肠癌患者中位生存期和生活质量的影响。方法采用随机对照临床研究方法,纳入晚期结直肠癌患者40例,可评价37例,治疗组18例,对照组19例,两组均采用化疗(FOLFOX、FOLFRI方案)等西医治疗,治疗组在此基础上加用祛...目的评价祛邪胶囊对晚期结直肠癌患者中位生存期和生活质量的影响。方法采用随机对照临床研究方法,纳入晚期结直肠癌患者40例,可评价37例,治疗组18例,对照组19例,两组均采用化疗(FOLFOX、FOLFRI方案)等西医治疗,治疗组在此基础上加用祛邪胶囊,治疗3个月后,进行长期随访,观察患者的病死率、生存期、中位生存期、疾病进展期(time to progression,TTP)及生活质量。结果治疗组和对照组的病死率分别为11.1%(2/18)和42.1%(8/19);生存期分别为(22.63±7.34)个月和(19.76±8.28)个月,中位生存期分别为17个月和13个月;TTP分别为(17.76±5.62)个月和(12.68±9.26)个月,经统计分析均有统计学意义(P<0.05)。中医症状积分、生活质量及KPS评分治疗组治疗前分别为15.59±3.78、54.06±3.96、64.71±6.24,治疗后分别为10.53±5.57、58.65±4.03、69.41±4.29,治疗前后比较差异均有统计学意义(P<0.05);对照组治疗前分别为16.11±3.99、54.06±4.39及64.44±5.11;治疗后分别为19.61±7.78、50.17±8.26、60.00±9.70,治疗前后生活质量及KPS评分比较差异有统计学意义(P<0.05),但趋势是向差的方向。结论晚期结直肠癌患者加用祛邪胶囊,能减少病死率,延长生存期、中位生存期和TTP,提高生活质量。展开更多
[目的]比较桡骨远端骨折内固定术后常规康复锻炼与加速康复锻炼的临床疗效,探讨两种康复锻炼方法的选择。[方法]采用临床随机对照的研究方法,根据纳入及排除标准选择桡骨远端骨折病例,共有179例患者纳入研究,其中常规组89例,加速组90例...[目的]比较桡骨远端骨折内固定术后常规康复锻炼与加速康复锻炼的临床疗效,探讨两种康复锻炼方法的选择。[方法]采用临床随机对照的研究方法,根据纳入及排除标准选择桡骨远端骨折病例,共有179例患者纳入研究,其中常规组89例,加速组90例。分别于切开复位掌侧接骨板内固定术后采用常规康复锻炼和加速康复锻炼。术后随访24周,观察患者上肢功能障碍评分（disability of arm shoulder and hand,DASH）、腕关节活动度、握力及三指捏力。[结果]术前两组患者DASH评分的差异无统计学意义（P〉0.05）,随着随访时间的延长,两组患者DASH评分均呈下降趋势。于随访2、3、4、6、8周和12周时,加速组患者的DASH评分明显低于常规组（P〈0.05）。两组患者腕关节背伸、掌屈,前臂旋前、旋后的活动度随随访时间的延长,均呈上升趋势。在各个随访时间点,加速组腕关节掌屈的活动度均明显大于常规组（P〈0.05）。于术后3、4、6周和8周时,腕关节背伸及前臂旋后的活动度均明显大于常规组（P〈0.05）。两组患者的握力及三指捏力均随着时间的推移呈上升趋势。于随访6、24周时,加速组的握力明显大于常规组（P〈0.05）。[结论]桡骨远端骨折采用掌侧接骨板内固定术后3-5 d即进行腕关节功能活动,并于术后2周后进行力量锻炼,可加快患肢功能恢复。展开更多
Objective:To evaluate the efficacy and safety of Chinese medicine(CM)improving pregnancy outcomes after surgery for endometriosis-associated infertility.Methods:A multicenter,randomized,doubleblind placebo parallel co...Objective:To evaluate the efficacy and safety of Chinese medicine(CM)improving pregnancy outcomes after surgery for endometriosis-associated infertility.Methods:A multicenter,randomized,doubleblind placebo parallel controlled clinical trial was designed.A total of 202 patients who had laparoscopy for endometriosis-associated infertility with qi stagnation and blood stasis syndrome were included and randomly divided into the CM treatment group and placebo control group at a ratio of 1:1 using a central block randomization from May 2014 to September 2017,101 patients in each group.The two groups received continuous intervention at 1–5 days after surgery,for 6 menstrual cycles.Before ovulation,the CM group was treated Huoxue Xiaoyi Granule(活血消异颗粒);after ovulation,Bushen Zhuyun Granule(补肾助孕颗粒)was involved.The control group was treated with placebo.Transvaginal ultrasonography was performed every menstrual cycle during the treatment,and female hormone levels in the follicular and luteal phases were measured during the 1 st,3 rd and 6 th menstrual cycles.The analysis was continued until pregnancy.The primary outcomes were clinical pregnancy rate and pregnancy outcome,and the secondary outcomes were follicular development and endometrial receptivity.Safety evaluations were performed before and after treatment.Results:(1)Clinical pregnancy and live birth rates:the clinical pregnancy and live birth rates of the CM group were significantly higher than those of the placebo group[44.6%(45/101)vs.29.7%(30/101),34.7%(35/101)vs.20.8%(21/101),both P<0.05].(2)Follicle development:the incidence of dominant follicles,rate of cumulative cycle ovulation,and rate of cumulative cycle mature follicle ovulation were significantly higher in the CM group than those in the placebo group[93.8%(350/373)vs.89.5%(341/381),80.4%(275/342)vs.69.1%(253/366),65.8%(181/275)vs 56.1%(142/253),P<0.05 or P<0.01]).The incidence of cumulative cycle luteinized unruptured follicle syndrome was significantly lower in the CM group tha展开更多
文摘目的评价祛邪胶囊对晚期结直肠癌患者中位生存期和生活质量的影响。方法采用随机对照临床研究方法,纳入晚期结直肠癌患者40例,可评价37例,治疗组18例,对照组19例,两组均采用化疗(FOLFOX、FOLFRI方案)等西医治疗,治疗组在此基础上加用祛邪胶囊,治疗3个月后,进行长期随访,观察患者的病死率、生存期、中位生存期、疾病进展期(time to progression,TTP)及生活质量。结果治疗组和对照组的病死率分别为11.1%(2/18)和42.1%(8/19);生存期分别为(22.63±7.34)个月和(19.76±8.28)个月,中位生存期分别为17个月和13个月;TTP分别为(17.76±5.62)个月和(12.68±9.26)个月,经统计分析均有统计学意义(P<0.05)。中医症状积分、生活质量及KPS评分治疗组治疗前分别为15.59±3.78、54.06±3.96、64.71±6.24,治疗后分别为10.53±5.57、58.65±4.03、69.41±4.29,治疗前后比较差异均有统计学意义(P<0.05);对照组治疗前分别为16.11±3.99、54.06±4.39及64.44±5.11;治疗后分别为19.61±7.78、50.17±8.26、60.00±9.70,治疗前后生活质量及KPS评分比较差异有统计学意义(P<0.05),但趋势是向差的方向。结论晚期结直肠癌患者加用祛邪胶囊,能减少病死率,延长生存期、中位生存期和TTP,提高生活质量。
文摘[目的]比较桡骨远端骨折内固定术后常规康复锻炼与加速康复锻炼的临床疗效,探讨两种康复锻炼方法的选择。[方法]采用临床随机对照的研究方法,根据纳入及排除标准选择桡骨远端骨折病例,共有179例患者纳入研究,其中常规组89例,加速组90例。分别于切开复位掌侧接骨板内固定术后采用常规康复锻炼和加速康复锻炼。术后随访24周,观察患者上肢功能障碍评分（disability of arm shoulder and hand,DASH）、腕关节活动度、握力及三指捏力。[结果]术前两组患者DASH评分的差异无统计学意义（P〉0.05）,随着随访时间的延长,两组患者DASH评分均呈下降趋势。于随访2、3、4、6、8周和12周时,加速组患者的DASH评分明显低于常规组（P〈0.05）。两组患者腕关节背伸、掌屈,前臂旋前、旋后的活动度随随访时间的延长,均呈上升趋势。在各个随访时间点,加速组腕关节掌屈的活动度均明显大于常规组（P〈0.05）。于术后3、4、6周和8周时,腕关节背伸及前臂旋后的活动度均明显大于常规组（P〈0.05）。两组患者的握力及三指捏力均随着时间的推移呈上升趋势。于随访6、24周时,加速组的握力明显大于常规组（P〈0.05）。[结论]桡骨远端骨折采用掌侧接骨板内固定术后3-5 d即进行腕关节功能活动,并于术后2周后进行力量锻炼,可加快患肢功能恢复。
基金Supported by the Key Projects of the National Science and Technology Pillar Program during the 12th Five-Year Plan Period(No.2014BAI10B08)
文摘Objective:To evaluate the efficacy and safety of Chinese medicine(CM)improving pregnancy outcomes after surgery for endometriosis-associated infertility.Methods:A multicenter,randomized,doubleblind placebo parallel controlled clinical trial was designed.A total of 202 patients who had laparoscopy for endometriosis-associated infertility with qi stagnation and blood stasis syndrome were included and randomly divided into the CM treatment group and placebo control group at a ratio of 1:1 using a central block randomization from May 2014 to September 2017,101 patients in each group.The two groups received continuous intervention at 1–5 days after surgery,for 6 menstrual cycles.Before ovulation,the CM group was treated Huoxue Xiaoyi Granule(活血消异颗粒);after ovulation,Bushen Zhuyun Granule(补肾助孕颗粒)was involved.The control group was treated with placebo.Transvaginal ultrasonography was performed every menstrual cycle during the treatment,and female hormone levels in the follicular and luteal phases were measured during the 1 st,3 rd and 6 th menstrual cycles.The analysis was continued until pregnancy.The primary outcomes were clinical pregnancy rate and pregnancy outcome,and the secondary outcomes were follicular development and endometrial receptivity.Safety evaluations were performed before and after treatment.Results:(1)Clinical pregnancy and live birth rates:the clinical pregnancy and live birth rates of the CM group were significantly higher than those of the placebo group[44.6%(45/101)vs.29.7%(30/101),34.7%(35/101)vs.20.8%(21/101),both P<0.05].(2)Follicle development:the incidence of dominant follicles,rate of cumulative cycle ovulation,and rate of cumulative cycle mature follicle ovulation were significantly higher in the CM group than those in the placebo group[93.8%(350/373)vs.89.5%(341/381),80.4%(275/342)vs.69.1%(253/366),65.8%(181/275)vs 56.1%(142/253),P<0.05 or P<0.01]).The incidence of cumulative cycle luteinized unruptured follicle syndrome was significantly lower in the CM group tha
